# Progress Note 07 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Judy Garland (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML005-SYN
- Date: 2026-10-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Margaret Ellsworth-Diaz, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

Four-month review: phenobarbital taper, sleep, mood and laboratory checks. **S**

## History of present illness

Ms. Garland returns four weeks after her preventive visit. She lowered phenobarbital to 40.5 mg a day at that visit and to 32.4 mg a day two weeks ago. After the last step she lay awake for three nights and felt shaky inside, without a tremor others could see; it has eased but not fully gone, and she would like to stay at this dose for a while. She has taken no secobarbital, stimulant or other sedative. She sleeps about six hours on most nights. Her mood is good and she is enjoying work again. She eats three meals on most days and says she feels stronger. Her HIV, hepatitis C and hepatitis B tests from the preventive visit were nonreactive, and she was told by phone. She wants to talk about stopping smoking once the taper is over. **S**

| Element | Detail |
|---|---|
| Phenobarbital | 32.4 mg a day for two weeks; three nights of rebound wakefulness after the step |
| Other sedatives or stimulants | None |
| Sleep | About six hours; Insomnia Severity Index 10 |
| Mood | PHQ-9 5; GAD-7 5 |
| Screening results | HIV, hepatitis C and hepatitis B nonreactive |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy good; weight up gradually |
| Neurological | Negative | No visible tremor or seizure-like episodes; brief inner shakiness after the last step, easing |
| Psychiatric | Negative | Mood good; PHQ-9 5; no thoughts of suicide or self-harm |

3 systems reviewed. **S**

## Current medications

- Sertraline 50 mg oral tablet, one tablet daily **S**
- Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a time **S**
- Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 50 kg; BMI 21.9 kg/m². All vital signs are synthetic.

Hemoglobin: 12.9 g/dL; MCV: 87 fL; Platelets: 268 10*3/uL; Ferritin: 41 ng/mL; Sodium: 140 mmol/L; Potassium: 4.2 mmol/L; Creatinine: 0.68 mg/dL; eGFR (CKD-EPI 2021): 118 mL/min/1.73 m²; AST: 23 U/L; ALT: 20 U/L; GGT: 48 U/L (high); PHQ-9: 5; GAD-7: 5. All results are synthetic.

## Change since baseline

- Hemoglobin: 12.3 g/dL at baseline, 12.9 g/dL at this visit **S**
- MCV: 86 fL at baseline, 87 fL at this visit **S**
- Platelets: 284 10*3/uL at baseline, 268 10*3/uL at this visit **S**
- Ferritin: 24 ng/mL at baseline, 41 ng/mL at this visit **S**
- Sodium: 139 mmol/L at baseline, 140 mmol/L at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.2 mmol/L at this visit **S**
- Creatinine: 0.66 mg/dL at baseline, 0.68 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 119 mL/min/1.73 m² at baseline, 118 mL/min/1.73 m² at this visit **S**
- AST: 21 U/L at baseline, 23 U/L at this visit **S**
- ALT: 18 U/L at baseline, 20 U/L at this visit **S**
- GGT: 24 U/L at baseline, 48 U/L (high) at this visit **S**
- PHQ-9: 14 at baseline, 5 at this visit **S**
- GAD-7: 13 at baseline, 5 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 112/70, pulse 68; weight 50.0 kg, BMI 21.9 |
| Neurological | No tremor with arms outstretched; no nystagmus |
| Psychiatric | Bright and engaged; no signs of sedation or withdrawal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Barbiturate use disorder on a phenobarbital taper** (F13.20). From 97.2 to 32.4 mg a day over fourteen weeks without a seizure or a return to secobarbital. The last step brought mild rebound wakefulness, so the taper is paused, as she asked. Urine test shows barbiturates only. Blood count normal; AST 23 and ALT 20 U/L normal; GGT 48 U/L, mildly raised by phenobarbital's effect on the liver's enzymes, to be rechecked after the taper. Safety reviewed: no thoughts of suicide or self-harm. **S**
   - Hold phenobarbital at 32.4 mg a day for four weeks, then 24.3, 16.2 and 8.1 mg a day, each for two to four weeks, and stop.
   - Addiction medicine review by video with Dr. Grünewald when the taper ends.
   - Repeat liver tests three months after stopping.
2. **Stimulant use disorder, mild, in early remission** (F15.10). No stimulant for twelve weeks; urine test negative for amphetamine. **S**
   - No stimulant prescriptions.
3. **Depression with anxious distress on sertraline** (F32.1). PHQ-9 5 from 14 and GAD-7 5 from 13: a good response, close to remission. **S**
   - Continue sertraline 50 mg daily for at least six to twelve months after remission.
   - Psychotherapy every two weeks.
4. **Chronic insomnia** (G47.00). Insomnia Severity Index 10 from 21; about six hours of sleep. **S**
   - Continue CBT-I every two weeks through the end of the taper.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Barbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs) | Every visit | Completed today | 32.4 mg a day; mild rebound wakefulness after the last step; no tremor or other withdrawal signs |
| Medication safety | Taper pace | Reductions of no more than about 20% every two weeks, slower toward the end; pause for symptoms, illness or a major performance | Completed today | 56.7 to 48.6 to 40.5 to 32.4 mg a day at two-week intervals; paused today for four weeks; later steps of 8.1 mg |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's prescriptions |
| Laboratory | Urine drug testing, explained as part of care | At the start, after the change to phenobarbital, and periodically during the taper | Completed today | Barbiturates only; amphetamine negative |
| Medication safety | Limited dispensing, locked storage and take-back of unused capsules | Seven days at first, then two weeks at a time | Completed today | Two-week supplies; locked box |
| Medication safety | Mood, sleep, energy and appetite after stopping the stimulant | Each visit | Completed today | No stimulant for twelve weeks; urges rare |
| Laboratory | Blood count and liver tests on phenobarbital | Baseline, then at three to four months | Completed today | Hemoglobin 12.9 g/dL, MCV 87 fL, platelets 268; ferritin 41 ng/mL; sodium 140, potassium 4.2, creatinine 0.68 mg/dL, eGFR 118; AST 23, ALT 20 U/L; GGT 48 U/L, mildly raised by enzyme induction |
| Survey | CBT for insomnia, sleep diary and Insomnia Severity Index | Weekly CBT-I sessions; sleep diary and index at each visit | Completed today | Insomnia Severity Index 10 |
| Medication safety | New hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine) | Not recommended as a replacement | Not indicated | No new hypnotic |
| Survey | Depression (PHQ-9) | At least monthly during acute treatment | Completed today | PHQ-9 5, item 9 scored 0; monthly since the corrective action |
| Survey | Anxiety (GAD-7) | With each PHQ-9 while anxiety is treated | Completed today | GAD-7 5 |
| Medication safety | Sertraline adherence and side effects | Two weeks after starting or changing the dose, then each visit | Completed today | 50 mg daily; no side effects |
| Survey | Suicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | C-SSRS screen negative since the last visit; the 988 Suicide & Crisis Lifeline in her phone |
| Examination | Weight, meals and disordered-eating screen, without a weight target | Every visit | Completed today | Weight 50.0 kg, BMI 21.9; three meals on most days; she feels stronger |
| Medication safety | Contraception that phenobarbital does not weaken | Medroxyprogesterone every 13 weeks | Up to date | Second injection at the preventive visit; next due in nine weeks |
| Medication safety | Naloxone | Reassess at every visit and whenever an opioid is prescribed | Not indicated | No opioids prescribed or used |
| Self-management | Alcohol and other sedatives | Every visit | Completed today | No alcohol; no other sedatives |

## Goal progress

- Change from secobarbital to phenobarbital under supervision without a withdrawal seizure or delirium. Outcome by 2026-07-20: Four-day supervised admission; no seizure, delirium or severe withdrawal. **S**
- Lower the phenobarbital dose slowly, at no more than about 20% every two weeks, toward stopping. Outcome by 2026-10-26: 97.2 mg a day at discharge to 32.4 mg a day at four months; two pauses when needed; taper continuing. **S**
- Stop dextroamphetamine with a short taper and no return to it. Outcome by 2026-08-31: Stopped after a two-week taper; tiredness for about two weeks, then better. **S**
- Sleep six hours or more on most nights using CBT for insomnia. Outcome by 2026-10-26: About six hours on most nights; rebound wakefulness after each dose step settles within a week. **S**
- PHQ-9 below 5 by six months. Outcome by 2026-10-26: PHQ-9 14 to 5 at four months; response. **S**
- Regular meals and weight she is comfortable with, without dieting drugs. Outcome by 2026-10-26: Three meals on most days; weight up 3.5 kg to a BMI of 21.9; she says she feels stronger. **S**

## Guideline basis

- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025), American Society of Addiction Medicine and nine partner organizations (J Gen Intern Med 2025;40(12):2814-2859)
- The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024), American Society of Addiction Medicine and American Academy of Addiction Psychiatry (Journal of Addiction Medicine)
- Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016), American College of Physicians (Annals of Internal Medicine)
- U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Nurse phone check before each remaining step. Visit in four weeks to restart the taper. Addiction medicine review when the taper ends. Smoking cessation plan at the end of the taper. **S**

